Jason O'Byrne - 01 Sep 2026 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: OLMA
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Sep 2026, 16:30:29 UTC
Prior SEC filing: 13 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Shawnte Mitchell, Attorney-in-Fact

Key filing fact

Jason O'Byrne filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 02 Sep 2026.

Key facts

This page summarizes Jason O'Byrne's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Sep 2026, 16:30.

Change

Previous filing in this sequence was filed on 13 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001871145 Primary reporting owner

O'Byrne Jason

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO
Signature: /s/ Shawnte Mitchell, Attorney-in-Fact
Signature date: 02 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OLMA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +650,000
Change %
Price: $0.000000^*
Shares after: 650,000
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 650,000
Exercise price: $10.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option vest on August 11, 2027 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.